Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Amazon Explores AI Content Marketplace With Media Publishers 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
SYDNEY, Australia and MINNEAPOLIS, Jan. 10, 2018 -- Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF) has received a Certificate of Compliance certifying that the Company’s Quality Management System complies with the requirements of ISO 13485. This also includes conformance with the Canadian Medical Device Conformity Assessment System (CMDCAS).
The certification was issued by DQS Med, the Notified Body appointed to assess Medibio’s submission for CE Mark. It signifies that Medibio has established a comprehensive quality system for the design and manufacturing of medical devices. ISO 13485 is recognized internationally as a universal measure of quality and is a critical prerequisite to securing CE Mark and other regulatory certifications.
“This is an major milestone for the Company,” said Medibio’s CEO & Managing Director, Mr. Jack Cosentino. “This accomplishment reflects the work of all individuals within the organization who all believe that this achievement of ISO certification echoes Medibio’s commitment to the highest level of quality management and to operational and production excellence.”
Following receipt of ISO certification, Medibio reaffirms its expectation of gaining CE Mark shortly.
About Medibio Limited
Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices located in Melbourne (Vic), and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.
Further Information: Website: www.medibio.com.au Medibio Shareholder Enquiries: Investor Relations Medibio Limited [email protected] T: +1 (952) 222-0551 Australian Media Enquiries: Peter Taylor NWR Communications [email protected] T: +61 (0) 412 036 231
